ArticleScientific reports2026
VB5 modulates osteoclast metabolic reprogramming and suppresses differentiation by blocking PKM2 nuclear translocation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a multifactorial skeletal disorder characterized by increased bone resorption and impaired remodeling balance. Osteoclast differentiation is accompanied by metabolic reprogramming toward enhanced glycolysis, yet whether nutritional factors modulate osteoclast metabolism remains incompletely understood. Vitamin B5 (VB5), a precursor of coenzyme A (CoA), has been implicated in metabolic regulation, but its role in osteoclast biology is unclear. An ovariectomy (OVX)-induced osteoporosis mouse model was established and fed VB5-deficient, normal, or VB5-supplemented diets. Bone microarchitecture was assessed by micro-computed tomography and histomorphometry. Osteoclast differentiation was evaluated in RAW264.7 cells and bone marrow-derived macrophages (BMDMs). Metabolic flux analysis, molecular docking, co-immunoprecipitation, and Western blotting were performed to investigate the involvement of the PANK-CoA-PKM2 axis. VB5 supplementation attenuated OVX-induced bone loss and reduced osteoclast numbers in vivo, whereas VB5 deficiency exacerbated bone deterioration. In vitro, VB5 and its metabolic derivative CoA suppressed osteoclast differentiation without inducing significant cytotoxicity. Mechanistically, VB5 increased intracellular CoA levels in a PANK-dependent manner. CoA interacted with PKM2, reduced Y105 phosphorylation, and decreased nuclear translocation, accompanied by suppression of glycolytic and oxidative phosphorylation activity. Pharmacological stabilization of PKM2 partially reversed molecular alterations associated with VB5 deficiency. VB5 is associated with inhibition of osteoclast differentiation and attenuation of estrogen deficiency-induced bone loss, potentially through modulation of metabolic reprogramming involving the PANK-CoA-PKM2 axis. These findings provide preliminary insight into a link between vitamin-dependent metabolic pathways and skeletal remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.